文献速递头颈外科

手术治疗的HPV相关口咽癌循环肿瘤HPV DNA的决定因素

Determinants of Circulating Tumor HPV DNA in Surgically Treated Oropharyngeal Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2026-01-01

该回顾性队列研究纳入104例接受 upfront 手术的HPV相关口咽鳞癌患者,分析术前和术后循环肿瘤HPV DNA(ctHPVDNA)与临床病理变量的关联。多变量分析显示,较高的eGFR和较高的病理N分期与较高的术前ctHPVDNA水平独立相关,而神经周围侵犯和病理结外延伸与较低水平相关。术后可检测到ctHPVDNA见于20.2%的患者,与超过4个阳性淋巴结和较高的术前ctHPVDNA水平相关。

要点

  • 较高的病理N分期和eGFR与术前ctHPVDNA水平升高独立相关。
  • 神经周围侵犯和病理结外延伸与较低的术前ctHPVDNA水平相关。
  • 术后可检测ctHPVDNA见于20.2%的患者,与阳性淋巴结数目和术前水平相关。

核心结论

  • 术前ctHPVDNA水平与病理N分期、eGFR、神经周围侵犯和病理结外延伸独立相关。
  • 术后可检测ctHPVDNA与超过4个阳性淋巴结及较高的术前ctHPVDNA水平相关。

研究设计与样本

  • 回顾性队列研究,在三级学术医疗中心进行,纳入2021年9月至2025年4月接受 upfront 手术的HPV相关口咽鳞癌患者。
  • 共104例患者有术前ctHPVDNA测量,其中74例有术前和术后评估。

主要发现

  • 术前ctHPVDNA平均(SD)水平为2786(9714)拷贝/mL。
  • 多变量负二项回归显示,较高的eGFR(RR=1.05,95%CI 1.01-1.09)和较高的病理N分期(RR=12.30,95%CI 2.65-57.5)与较高的术前ctHPVDNA水平独立相关。
  • 神经周围侵犯(RR=0.23,95%CI 0.07-0.83)和病理结外延伸(RR=0.11,95%CI 0.04-0.28)与较低的术前ctHPVDNA水平相关。
  • 术后可检测ctHPVDNA见于15/74例(20.2%),与超过4个阳性淋巴结(OR=4.86,95%CI 1.39-19.49)和较高的术前ctHPVDNA水平(OR=1.17,95%CI 1.04-1.36)相关。
  • 术后可检测ctHPVDNA患者中3/15例(20.0%)复发,而术后不可检测患者中8/59例(13.6%)复发。

临床怎么用

  • 术前ctHPVDNA水平受肾功能、病理N分期、神经周围侵犯和结外延伸影响,解读时需考虑这些因素。
  • 术后可检测ctHPVDNA与高危病理特征相关,可能有助于识别复发风险较高的患者。

局限性

  • 回顾性研究设计。
  • 单中心研究。
  • 部分患者缺乏术后ctHPVDNA数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Circulating tumor DNA (ctDNA) is a biomarker of disease status in patients with human papillomavirus (HPV)-mediated oropharyngeal squamous cell carcinoma (OPSCC). OBJECTIVE: To assess clinicopathologic variables associated with circulating tumor human papillomavirus DNA (ctHPVDNA) before and after surgery. DESIGN, SETTING, AND PARTICIPANTS: The retrospective review and cohort study was conducted at a tertiary academic medical center and included patients with HPV-mediated OPSCC who were treated with upfront surgery between September 2021 and April 2025. Data were analyzed between September 2025 and December 2025. EXPOSURES: Clinicopathologic variables, including demographic characteristics, pathologic T and N stage, American Joint Committee on Cancer Staging Manual, 8th edition stage, tumor size, margin status, pathologic extranodal extension (pENE), and lymphovascular and perineural invasion. MAIN OUTCOMES AND MEASURES: Multivariable negative binomial regression was used to identify clinicopathologic factors associated with preoperative ctHPVDNA, which was measured using tumor tissue-modified viral HPV DNA. Factors associated with detectable postoperative ctHPVDNA were evaluated using logistic regression. RESULTS: A total of 104 patients (mean [SD] age, 59 [10] years; 20 female individuals [19%] and 84 male individuals [81%]; 3 Black individuals [3%] and 101 White individuals [97%]) with HPV-associated OPSCC who were treated with upfront surgery had preoperative ctHPVDNA measurements, and 74 patients had preoperative and postoperative assessments. The mean (SD) preoperative ctHPVDNA level was 2786 (9714) copies/mL. On multivariable negative binomial regression, higher estimated glomerular filtration rate (eGFR; rate ratio [RR], 1.05; 95% CI, 1.01-1.09) and higher pathologic N stage (RR, 12.30; 95% CI, 2.65-57.5) were independently associated with higher preoperative ctHPVDNA levels, whereas perineural invasion (PNI; RR, 0.23; 95% CI, 0.07-0.83) and pathologic extranodal extension (pENE; RR, 0.11; 95% CI, 0.04-0.28) were associated with lower levels. Detectable postoperative ctHPVDNA was observed in 15 of 74 patients (20.2%) and was associated with more than 4 positive lymph nodes (odds ratio [OR], 4.86; 95% CI, 1.39-19.49) higher preoperative ctHPVDNA levels (OR, 1.17; 95% CI, 1.04-1.36), PNI (OR, 2.95; 95% CI, 0.51- 15.51), and pENE (OR, 3.38; 95% CI, 0.84-13.29). Recurrence occurred for 3 of 15 patients (20.0%) with detectable postoperative ctHPVDNA compared with 8 of 59 patients (13.6%) with undetectable ctHPVDNA. Among patients with undetectable postoperative ctHPVDNA, 4 locoregional recurrences occurred in individuals who declined guideline-concordant adjuvant therapy. CONCLUSIONS AND RELEVANCE: The results of this cohort study illuminate the biological and clinical factors associated with ctHPVDNA shedding and clearance, potentially offering guidance for integrating ctHPVDNA into biomarker-driven clinical trials.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Birkenbeuel JL, Noel C, Baliga S, et al. Determinants of Circulating Tumor HPV DNA in Surgically Treated Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 41926134. doi:10.1001/jamaoto.2026.0015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。